27 sep: Resultat af fortegningsretsemission i Vestjysk Bank
27 sep: Debitormassens sammensætning for konverterbare obligationsserier,..
27-09-2017 09:00:00

ALK’s partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan

Relateret indhold
10 nov - 
Fredagens aktier: C20 i rødt efter fortsat nedtur for V..
10 nov - 
Aktier/middag: Vestas, Mærsk og Pandora trækker C20 i r..
10 nov - 
ALK Q3: Husstøvmidetablet nærmer sig markedet i USA - N..
Relateret debat
11 nov - 
Lad nu den bolle få et engelskkursus. Det er måske det ..
10 nov - 
Suppleret lidt op med 28 stk til 929 til nu 168 her til..
10 nov - 
Tallene er ikke specielt skuffende, men nogenlunde på l..

Copenhagen, 2017-09-27 09:00 CEST (GLOBE NEWSWIRE) --

 

  • CEDARCURE™ is the first SLIT-tablet to be approved for both adult and paediatric use in Japan

  • Joins the already launched MITICURE™ (ACARIZAX® in Europe) in Torii’s allergy portfolio, effectively completing the coverage of allergies in Japan

  • ALK entitled to receive royalties on sales of CEDARCURE™

  • ALK’s financial guidance for 2017 remains unchanged 

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Japan’s Ministry of Health, Labour and Welfare has approved the New Drug Application submitted by its partner Torii Pharmaceutical Co., Ltd., for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, which will be branded CEDARCURE™. 

CEDARCURE™ is based on the same SLIT-tablet technology used in ALK’s grass, ragweed and house dust mite SLIT-tablets, and was developed by Torii with support from ALK specifically for the Japanese market, where Japanese cedar pollen is a major allergen. 

Japan is the world’s second largest market for allergy medicine after the USA. Around 25% of Japan’s population suffer from allergic rhinitis (AR), with around 70% of AR sufferers having a specific allergy to Japanese cedar pollen. Japanese cedar allergy can affect people of all ages but recent research shows that the typical age of onset is falling. 

CEDARCURE™ has been approved for hyposensitisation therapy (allergy immunotherapy) for the treatment of Japanese cedar pollinosis (allergic rhinitis) in adults and children, and is the first SLIT-tablet to be approved for both adult and paediatric use in Japan. 

Carsten Hellmann, ALK’s President and CEO says: “This approval marks the culmination of several years of successful R&D collaboration between ALK and Torii, a partnership that we anticipate will bring many more years of commercial return. It also means another successful approval for the SLIT-tablet technology that underpins our global range of standardised, registered allergy immunotherapy treatments, adding Japanese cedar to a range that includes grass, ragweed and house dust mite treatments, with a tree tablet to be added in the foreseeable future.” 

ALK’s partnership with Torii was announced in 2011, and covers the development, registration and commercialisation of CEDARCURE™ as well as ALK’s house dust mite SLIT-tablet, ACARIZAX®, which was approved for adult use in Japan in 2015 and launched under the Torii brand name of MITICURE™. In March 2017, Torii also submitted a paediatric registration application for MITICURE™ based on positive Phase III clinical data. 

A launch date for CEDARCURE™ will be announced by Torii after price and reimbursement have been agreed upon with the National Health Insurance. 

ALK is entitled to receive royalties on the sales of CEDARCURE™ which will be booked as partner revenue from International markets. This announcement does not change ALK’s 2017 financial outlook. 

ALK-Abelló A/S

 

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

 

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

About Torii Pharmaceutical Co., Ltd.

Established in 1921, Torii Pharmaceutical Co., Ltd., manufactures and markets pharmaceutical products in four main therapeutic areas: renal diseases and haemodialysis, skin diseases, HIV, and allergy. The company has approximately 1,000 employees, is headquartered in Tokyo and is listed on the Tokyo Stock Exchange (TSE:4551). Read more at www.torii.co.jp.

Vedhæftet fil: FM_26_17UK_27092017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Mærsk-aktien får comeback og har bedste børsdag i fire måneder

24-11-2017 15:11:54
A.P. Møller-Mærsk har haft en hård periode på børsen efter selskabets regnskab tidligere på måneden, men fredag får aktien lidt tiltrængt medvind.Aktien stiger fredag eftermiddag 3,6 pct. til 10.500 kr., hvilket er den højeste stigning på én dag siden begyndelsen af juli.- Mærsk-aktien har fået rimeligt mange klø på det seneste, og så skal man også have in mente, at der er tynd volumen i markedet ..

Mærsk: Rateindeks falder til laveste i 15 måneder trods lyspunkt -NY

24-11-2017 13:35:30
SCFI-indekset over rateudviklingen på en stribe ruter fra Shanghai og ud i verden faldt igen denne uge.Indekset faldt 3,9 pct. til 705,2, viser nye data fra Shanghai Shipping Exchange, og tager dermed sit tredje dyk i træk. Indekset ligger nu på det laveste niveau siden august 2016.Ugens aflæsning er desuden 16 pct. lavere end snitniveauet hidtil i år. Raterne dykkede, selv om der var mere positiv..

Aktier/åbning: Køkkenkoncern får rolig børsdebut i uændret marked

24-11-2017 09:14:57
Køkkenkoncernen TCM Group, der blandt andet ejer brands som Svane Køkkenet og Tvis Køkkener, får fredag en noget stille debut på den københavnske fondsbørs.Resten af markedet udvikler sig også generelt roligt, og der er heller ikke større nyheder eller kommende offentliggørelser på tapetet. Det danske eliteindeks stiger knap 0,1 pct. til 1115,86 kort efter børsåbningen.Herhjemme er C20 Cap-indekse..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Jyske: Resultatet før skat vil nærme sig 5 mia. kr. i 2019 - NY
2
C20 Cap har haft længste nedtur i tre år
3
Aktier/tendens: Køkkenkoncern får børsdebut i ventet positivt marked
4
Analytiker: Boligejere med variable lån risikerer at udhule friværdien
5
Fredagens aktier: Mærsk og FLSmidth hver sin vej i rødt C20

Relaterede aktiekurser

ALK-Abelló B A/S 896,00 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. november 2017 00:45:21
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB3 - 2017-11-25 00:45:21 - 2017-11-25 00:45:21 - 1 - Website: OKAY